Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting
Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clinical Genitourinary Cancer 2017, 16: 50-57. PMID: 28729067, DOI: 10.1016/j.clgc.2017.06.004.Peer-Reviewed Original ResearchAndrogen receptor-targeted therapiesMetastatic castration-resistant prostate cancerSecond-line TTReceptor-targeted therapyProstate-specific antigenOverall survivalOpioid useAlbumin levelsMedian prostate-specific antigenSecond-line therapy initiationCastration-resistant prostate cancerResponse rateSevere disease profilesSecond-line therapyPoor prognosis patientsOptimal treatment sequenceOutcomes of patientsAlkaline phosphataseImproved OSPrognosis patientsTherapy initiationProstate cancerLow hemoglobinPoor prognosisMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply